Delphi advisor to AddLife in double acquisitions

Delphi has assisted AddLife AB (publ) in connection with two acquisitions – Healthcare 21 Group and Vision Ophthalmology Group. The acquisitions were closed on the 12th and 8th of April 2021.

AddLife is an independent distributor within Life Science that offers high-quality products, services and advice to both the private and public sectors. The corporation owns and acquires market-leading companies in niche segments within the healthcare sector.

Healthcare 21 Group is a leading independent Life Science distributor with operations in Ireland and the United Kingdom. The company has a revenue of approximately EUR 171 million and about 450 employees. The acquisition establishes AddLife in Ireland and the United Kingdom. The total purchase price amounts to EUR 240 million, of which 74 percent is paid in cash and 26 percent through newly issued B shares. The transaction also includes an additional consideration of up to a maximum of EUR 5 million.

Vision Ophthalmology Group GmbH is a leading European distribution and manufacturing company in ophthalmology with operations in Switzerland, Germany, the United Kingdom and Poland. The company has a revenue of approximately EUR 70 million and about 190 employees. The acquisition adds a new therapeutic segment to AddLife’s product portfolio. The total purchase price amounts to EUR 165 million, of which 50 percent is paid in cash and 50 percent through existing repurchased and newly issued B shares. The transaction also includes an additional consideration of up to a maximum of EUR 18 million.

Read more about the two acquisitions in AddLife’s press releases here.

Delphi’s team consisted of Mats Dahlberg, Fredrik Mörner, Michael Juhlin, Glenn Nyström, Berndt Pettersson, Karin Roberts and Emil Blomqvist.